Every baby deserves the healthiest start. Our groundbreaking study shows babies given personalized microbiome support had 83% lower odds of eczema risk and improved gut health. Published in Pediatric Allergy and Immunology.
‍DOI: 10.1111/pai.70182


of children in the U.S. live with at least one chronic condition
children in the U.S. have a diagnosed allergic disease
increase in atopic dermatitis over the past three decades
C-sections, antibiotics, and other interventions are sometimes necessary, but they can affect a baby's health in ways many parents don't realize. During vaginal birth, babies are exposed to beneficial bacteria from their mother. If anything disrupts this process, or if mom is missing key bacteria, their baby may miss this crucial first dose of healthy microbes which can lead to:
The Infant Restore study followed 54 healthy C-section babies for 3 months. Babies who received personalized microbiome testing, targeted probiotics, and expert guidance had dramatically better outcomes—including 83% lower odds of developing eczema compared to babies who received no intervention.
These are the highlight results from our randomized controlled trial, published in Pediatric Allergy and Immunology, Sept 2025
Babies in the program had much higher levels of Bifidobacterium, the beneficial bacteria that help babies digest breastmilk nutrients, build a strong immune system, and lower the risk of chronic inflammation.
These babies showed stronger ability to break down and use the healthy components in breastmilk that can help develop the immune system and reduce the risk of viral and bacterial infections.
Parents reported significantly fewer health issues in babies who received the targeted microbiome support, especially allergic conditions.
By the end of the study, C-section babies who got personalized support had gut bacteria that closely resembled vaginally-born babies—a complete transformation.
We measured multiple health markers in these babies over six months. The results tell a powerful story: personalized microbiome support transforms gut health, strengthens digestion, and reduces disease risk across the board.
Figure 1. Relative abundance of Bifidobacterium infantis across both groups and time points. Median B. infantis relative abundance at time point 2 was 61% in the intervention group vs. 3.4% in controls (p = 0.001, q = 0.013). The thick line within the box represents the median, and the lower and upper boxes represent the 25th and 75th quartiles of the data, respectively. Individual values are shown as circles. Significance: q < 0.05 **, q < 0.01 ***, n.s. = not significant.
Figure 2. Gene levels of sialidase across both groups and time points. These HMO-degrading genes increased in the intervention group (p = 0.019, q = 0.046; and p = 0.012, q = 0.033, respectively). The thick line within the box represents the median, and the lower and upper boxes represent the 25th and 75th quartiles of the data, respectively. Individual values are shown as circles. Significance: q < 0.05 **, q < 0.01 ***, n.s. = not significant.
Figure 3. C-section index at time points 1 and 2 for both study groups, compared to C-section- and vaginally-delivered infants from Shao et al. (2019). Â The thick line within the box represents the median, and the lower and upper boxes represent the 25th and 75th quartiles of the data, respectively. Individual values are shown as circles. Significance: q < 0.1 *, q < 0.01 ***, n.s. = not significant.
Figure 4. Percentage of infants with any reported health conditions at each time point. By the end of the study, the intervention group had fewer infants with reported health conditions overall (p = 0.004).

Get the same personalized microbiome care that helped babies in our study thrive. Test your baby's gut, get expert guidance, and reduce their risk of eczema and other health issues.